Design Therapeutics Stock (NASDAQ: DSGN) stock price, news, charts, stock research, profile.
Open | $3.770 |
Close | $3.780 |
Volume / Avg. | 108.094K / 262.004K |
Day Range | 3.695 - 3.800 |
52 Wk Range | 1.940 - 8.470 |
Market Cap | $213.548M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 56 |
Short Interest | 6.53% |
Days to Cover | 4.42 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Design Therapeutics (NASDAQ: DSGN) through any online brokerage.
Other companies in Design Therapeutics’s space includes: Zura Bio (NASDAQ:ZURA), Renovaro (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Galectin Therapeutics (NASDAQ:GALT) and Adverum Biotechnologies (NASDAQ:ADVM).
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on Wednesday, March 20, 2024. The analyst firm set a price target for 4.00 expecting DSGN to rise to within 12 months (a possible 5.82% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Design Therapeutics (NASDAQ: DSGN) is $3.78 last updated April 26, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Design Therapeutics.
Design Therapeutics’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Design Therapeutics.
Design Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.